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Abstract A link between eortieosteroid therapy and the 
development of cataract has been known for many years. 
However, the precise underlying molecular mechanism of 
pathology has not been characterised, although a role for direct 
deleterious interactions between corticosteroids and lenticular 
proteins has been investigated. ¢x-Crystallin is a major lens 
protein that has exhibited chaperone properties in vitro. Catalase 
is a ubiquitous enzyme that is an important scavenger of 
hydrogen peroxide in vivo. The corticosteroid prednisolone-21- 
hemisuccinate was found to inactivate bovine liver catalase, in 
vitro in a progressive manner. Coincubation of ~-crystallin with 
catalase in a 1:2 molar ratio (one c¢-crystallin to two catalase 
molecules) fully protected against this inactivation. The protec- 
tion was specific. Aspirin-like analgesics, putative anti-cataract 
drugs offered no such protection. 
Key words: Catalase; Prednisolone-21-hemisuccinate; c~- 
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1. Introduction 
Catalase (EC 1.11.1.6) and glutathione peroxidase (EC 
1.11.1.9) break down the potentially harmful hydrogen per- 
oxide in cells [1]. Loss of activity of one of these enzymes 
could leave tissues vulnerable to peroxide induced damage. 
In human cataract and in experimentally induced cataracts 
the activities of some important enzymes, including catalase 
fall [2,3]. Evidence that steroids could induce cataract has 
accumulated since Black et al. observed that rheumatoid ar- 
thritis patients administered oral corticosteroids had a signifi- 
cant association with the development of posterior subcapsu- 
lar cataract [4]. Such conclusions have been confirmed in 
various epidemiological studies [5-7]. Steroid-induced cata- 
racts have been observed in rabbit [8] and chick embryo [9] 
models after injection with corticosteroids. Glucocorticoid 
protein adducts have been observed in human lenses of cata- 
ract patients who had previously undergone glucocorticoid 
therapy and in rat lenses incubated with prednisolone [10]. 
A mechanism by which a corticosteroid could inactivate an 
enzyme would be via an attack by a reactive carbonyl group 
at C-20 on a free c~-amino group or the e-amino groups of 
lysine residues. Prednisolone-21-hemisuccinate contains uch a 
reactive carbonyl group. After formation of a Schiff base, a 
rearrangement to a more stable Heyns product could occur 
which would contain another eactive carbonyl group [8]. Cat- 
alase, although its N-terminus is blocked, contains 92 lysine 
residues per tetramer. Seventy two of these groups are ex- 
posed on the surface of the molecule [11], some of these 
may be susceptible to post translational modification. The 
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level of glucose in the lens increases in steroid induced cata- 
ract [9]. Thus problems involved with high steroid concentra- 
tions in vivo could be augmented by sugar-induced attack of 
lens proteins. 
~-Crystallin, a major lens protein, has sequence homology 
to the small heat shock proteins [12] and exhibits chaperone 
activity in vitro [13]. The first evidence of a chaperone role for 
a-crystallin came from the observation by Horwitz that c~- 
crystallin could suppress the thermally-induced aggregation 
of 13L and T crystallin and that of a variety of enzymes [14]. 
Evidence for additional physiological roles for c~A and c~B, 
the subunits for a-crystallin, besides that of maintaining the 
structural integrity of the lens has come from the finding that 
their expression is not confined to the lens [15-17]. Elevated 
levels of ~B crystallin mRNA or protein are associated with a 
variety of pathological conditions [16,18]. More recently, this 
protein has been shown to fully protect against glycation-in- 
duced inactivation of glucose-6-phosphate dehydrogenase [19]. 
This is consistent with a chaperone function, a-Crystallin has 
not been crystallised, so its structure/function relationship re- 
mains to be elucidated. Several models for the quaternary 
structure have been suggested [20-23]. 
Aspirin-like analgesics, including aspirin, delayed the onset 
of diabetic cataract in rats [24,25]. Epidemiological studies 
have shown a reduced risk of cataract associated with regular 
intake of non steroidal anti-inflammatory drugs [5,26,27]. As- 
pirin and ibuprofen have also been shown to significantly 
reduce potentially deleterious modifications of lens proteins 
in vitro, such as glycosylation [28]. 
In the results presented we show that prednisolone-21-hemi- 
succinate inactivates catalase in vitro, a-Crystallin fully and 
specifically protected against this inactivation over several 
days in a 1:2 molar ratio to that of catalase. The aspirin- 
like analgesics did not offer any significant protection against 
steroid-induced inactivation of catalase. 
2. Materials and methods 
2.1. Materials 
c¢-Crystallin was isolated from bovine lenses by gel chromatography 
on Sephacryl $300 HG using the method of Slingsby and Bateman 
[29]. Bovine liver catalase, egg lysozyme, bovine serum albumin, pred- 
nisolone-21-hemisuccinate and all other proteins and chemicals were 
obtained from Sigma, Poole, Dorset, UK. 
2.2. Incubation 
Catalase (523 units, 24.9 btg) was incubated in a shaking water bath 
in 50 mM sodium phosphate buffer, pH 7 with and without 1 mM 
and 2 mM prednisolone-21-hemisuccinate for b tween 1and 6 days in 
a final volume of 1 ml. 
In some experiments, et-crystallin, bovine serum albumin, lysozyme, 
human albumin, egg albumin, c~-chymotrypsinogen, ribonuclease and 
glucose oxidase (each at 20 ~tg/ml) were added to different vials during 
the incubation. Alternatively aspirin, paracetamol and ibuprofen 
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Fig. 1. Inactivation of catalase in the absence (O) and presence of l 
mM (11), 2 mM (* )  and 5 mM (v )  prednisolone-21-hemisuccinate, 
(each at 10 mM) were added to different vials. Each solution was then 
inoculated through sterile 0.2 ].tm Nalgene syringe filters into sealed, 
autoclaved sterile vials. 
2.3. Assays 
Enzyme activity was assayed by monitoring the decreased absor- 
bance at 240 nm resulting from the decomposition of hydrogen per- 
oxide for 1 min at 37°C. The assay mixture consisted of 2.5 ml of 
H202 solution from a stock solution of 0.1 ml of 30% H202 diluted in 
50 ml of sodium phosphate buffer, pH 7, and 20 gl of the incubation 
solution, made up to a final volume of 3 ml with the phosphate buffer. 
All assays (3.5 units, 0.17 gg) were carried out in triplicate. Activity is 
expressed relative to the control activity at each respective time inter- 
val, set at 100%, unless otherwise stated. 
2.4. Fluorescence 
Incubated samples were dialysed extensively against 50 mM sodium 
phosphate buffer, pH 7 and 800 gl of the sample was excited at 295 
nm and measured for tryptophan fluorescence, slit width 10 nm, emis- 
sion spectra of 300 to 500 nm, on a Perkin Elmer LS 50 B lumines- 
cence spectrometer. 
2.5. High-pressure liquid chromatography 
Incubation solutions (2 ml) were dialysed against volumes of 100 ml 
50 mM phosphate buffer and 1 vol. 100 ml distilled water at 1 h 
intervals over 4 h. 1.5 ml of each solution was then freeze dried, 
samples were reconstituted in 50 gl of distilled water and 30 gl was 
then loaded onto a Biosep $4000 size-exclusion column (Phenoyenex, 
Macclesfield, UK) and eluted at 0.5 ml/h. Absorption at 280 nm was 
followed and 1 min fractions were collected, 400 gl of which were 
assayed for catalase activity as described above. 
2.6. Statistical analysis 
All results were subjected to a Student's t-test where relevant. 
3. Results 
The effect of the glucocorticoid prednisolone-21-hemisucci- 
nate on catalase activity was followed. Prednisolone-21-hemi- 
succinate inactivated catalase in a slow, steady, progressive 
manner  (Fig. 1). There was no immediate inhibit ion at time 
zero which clearly indicates that the inactivation was due to 
slow post-translat ional modification of catalase by the steroid. 
Prednisolone-21-hemisuccinate at concentrat ions of 1, 2 and 5 
mM seemed to inactivate in a dose-dependent manner,  but the 
different rates of inactivation were not found to be signifi- 
cantly different according to a Student's t-test. Extensive dia- 
lysis of incubation solutions had no effect on the degree of 
inactivation, suggesting a strong interaction between predni- 
solone-21-hemisuccinate nd catalase. The emission maxima 
of the catalase solution containing 1 mM prednisolone-21- 
hemisuccinate did not differ significantly from that of the 
control solution containing just catalase after upto 8 days of 
incubation suggesting that no steroid-induced gross confor- 
mat ional  change such as dissociation or aggregation had oc- 
curred. Rather we would suggest hat the site of initial reac- 
tion between a prednisolone-21-hemisuccinate and a catalase 
molecule is likely to be one at or near the active site that 
would have the result of inactivation with only a limited con- 
formational change being induced. A good candidate for such 
a modif ication would be Lys 236 (bovine liver), the most 
charged residue on the outside of the catalase molecule [11]. 
It is an unusual residue in that it is found in a hydrophobic 
environment in the interior of a I~ barrel domain of catalase. 
Such a hydrophobic environment one could postulate would 
stabilise the reaction of a glucocorticoid with a protein. 
~-Crystal l in protected against the inactivation of catalase 
by 1 and 2 mM prednisolone-21-hemisuccinate (Fig, 2). I f  
we assume that under native conditions cc-crystallin exists as 
a complex of 800 kDa [30], then 0.05 }aM (40 gg/ml) a-crystal- 
lin fully protected against the inactivation by 1 and 2 mM 
prednisolone-21-hemisuccinate in a 1:2 molecular weight ratio 
to that of catalase [1]; i.e. each molecule of c~-crystallin pro- 
tected two molecules of catalase. Only 24% of control activity 
remained after 4 days of incubation with 1 mM prednisolone- 
21-hemisuccinate alone, but with 1 mM prednisolone-21- 
hemisuccinate and c~-crystallin, catalase remained fully active 
at 4 days (P = 0.001). After 6 days only 9% of control activity 
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Fig. 2. The % of control enzyme activity of catalase in the absence 
((3) and presence of 1 mM (I) or 2 mM (v )  prednisolone-21-hemi- 
succinate was assayed, a-Crystallin was present at 40 gg/ml in other 
solutions containing catalase and 1 mM (A) and 2 mM (0)  predis- 
olone-21-hemisuccinate that were assayed at the same time intervals 
over 6 days. 
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Fig. 3. The % of control enzyme activity of catalase in the absence 
(©) and presence of 2 mM prednisolone-21-hemisuccinate (m) was 
assayed. Other incubations including 20 ~g/ml of (x-crystallin (A), 
bovine serum albumin (• )  or egg lysozyme (•) ,  in addition to cat- 
alase and 2 mM prednisolone-21-hemisuccinate wer also assayed 
over 6 days. 
remained upon incubation with 1 mM prednisolone-21-hemi- 
succinate alone, but at this time the addition of ct-crystallin 
conferred the retention of 83% of control activity (P = 0.021). 
Additionally, just 25% of control activity remained after 3 days 
of incubation with 2 mM prednisolone-21-hemisuccinate, bu  
with 2 mM prednisolone-21-hemisuccinate and ct-crystallin, 
full protection was again conferred to catalase (P = 0.004). 
However, after 6 days only 4% of control activity remained 
upon incubation with 2 mM prednisolone-21-hemisuccinate, 
whereas with 2 mM prednisolone-21-hemisuccinate and c(- 
crystallin 57% of control activity remained. This protective 
effect was found not to be statistically significant (P = 0.117). 
Clearly, t~-crystallin could fully protect against inactivation by 
prednisolone-21-hemisuccinate for a limited period of time. It 
is of note that none of the previously postulated anti-cataract 
drugs, aspirin, paracetamol r ibuprofen at the comparatively 
high concentration of 10 mM, could confer any lasting pro- 
tection against his inactivation (results not shown). 
The protection conferred by tx-crystallin was found to be 
specific. This is shown by incubations of catalase and 2 mM 
prednisolone-21-hemisuccinate with concentrations of ct-crys- 
tallin or other proteins at 20 gg/ml, half the w/v concentration 
of ct-crystallin in the previously described experiments. Fig. 3 
shows that neither bovine serum albumin nor lysozyme af- 
forded any protection against he inactivation of catalase by 
2 mM prednisolone-21-hemisuccinate. Aft r2 days only 25% 
of control activity remained in the incubation with 2 mM 
prednisolone-21-hemisuccinate alone but with 2 mM predni- 
solone-21-hemisuccinate and ct-crystallin, 84% of control ac- 
tivity remained (P = 0.024). After 6 days of incubation, only 
6% of control activity was found in the solution of 2 mM 
prednisolone-21-hemisuccinate, however with 2 mM predniso- 
lone-21-hemisuccinate nd et-crystallin only 35% of control 
activity remained which was found not to be significant 
(P = 0.316). It is of note that 10 pg/ml t~-crystallin protected 
against he inactivation by 2 mM prednisolone-21-hemisucci- 
nate after 1 day (P=0.014), result not shown. Bovine serum 
albumin (and human albumin) have twice as many lysines per 
100 amino acid residues as c(-crystallin and so if ct-crystallin 
were protecting against steroid inactivation by non-specifically 
reacting with these molecules itself, one would expect bovine 
serum albumin to protect in a similar fashion. In other experi- 
ments five other proteins were incubated with catalase instead 
of tx-crystallin. Again no other proteins were able to protect 
against he steroid-induced inactivation of catalase (Fig. 4). ct- 
Crystallin at 20/.tg/ml was able to afford both significant and 
specific protection for upto 2 days. In summary, ct-crystallin 
at a concentration equal to 0.05 ~tM significantly and fully 
protected against steroid inactivation over a period of 4-6 
days when incubated with 2 and 1 mM prednisolone-21-hemi- 
succinate, respectively. 0.025 /.tM c(-crystallin protected to a 
lesser extent, but protection was statistically significant for at 
least 2 days. This protection was specific and lower concen- 
trations of e(-crystallin conferred very limited protection. 
One interesting observation from Figs. 2~4 is that the activ- 
ities of solutions containing ct-crystallin are higher than that 
of the control, at early incubation periods. This apparent 
anomaly could be explained by our findings that activity of 
the control enzyme itself decreases to around 60% of its initial 
day 0 activity after a period of 6 days. Catalase incubated 
with tx-crystallin alone lost less activity over the same period 
of time, activity being around 80% of that of the initial con- 
trol day 0 activity (results not shown). It also appeared that 
the presence of c(-crystallin increases the activity of catalase 
almost immediately. Therefore, tx-crystallin may be able to 
protect against catalase heat lability at 37°C. 
Size-exclusion chromatography was carried out to investi- 
gate complex formation. No separate peak indicating a com- 
plex of molecular weight greater than that of ct-crystallin was 
observed even after 6 days of incubation (results not shown), 
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Fig. 4. The % of control enzyme activity of catalase in the absence 
(©) or presence of 2 mM prednisolone-21-hemisuccinate (11) were 
assayed. Other incubations including 20 ~tg/ml of ct-crystallin (*), 
human albumin (•),  egg albumin (•) ,  tt-chymotrypsinogen (o), ri- 
bonuclease (v) and glucose oxidase (E]) with catalase and 2 mM 
prednisolone-21-hemisuccinate were also assayed over 6 days. 
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although the possibility of complex dissociation during the 
isolation process cannot be excluded. To determine whether 
catalase was protected by forming a stable complex without a 
significant increase in size of c~-crystallin, we measured the 
catalase activity in the ~-crystallin containing fractions. No 
activity was found in this fraction. Catalase activity was only 
found in the fractions corresponding to tetrameric atalase. 
During the 6 days of incubation of prednisolone-21-hemisuc- 
cinate and catalase with a-crystallin there was an increase in 
the size of the ~-crystallin peak relative to the catalase peak 
(results not shown). In incubations carried out without the 
steroid, this change in relative size was not seen. 
4. Discussion 
Prednisolone-21-hemisuccinate inactivated catalase. Enzyme 
levels fall during the onset of steroid-induced cataract [2,3]. All 
prednisolone-21-hemisuccinate molecules would potentially be 
reactive and as these molecules are in a large molar excess to 
catalase molecules in a ratio of at least 10 000:1 in our in vitro 
system, any system of protection by a protein would have to 
be more elaborate than simply that of it reacting with predni- 
solone-21-hemisuccinate itself. The results presented here offer 
evidence for the role of a-crystallin as a molecular chaperone 
in vitro. If every lysine residue of a-crystallin reacted with a 
prednisolone-21-hemisuccinate mol cule (at concentrations 
shown in Figs. 3 and 4) assuming that the lysine residue con- 
centration of c~-crystallin was as high as 10 IxM and that all the 
prednisolone-21-hemisuccinate molecules were in an active 
state, then there would still be 199 prednisolone-21-hemisucci- 
nate molecules out of every 200 left in solution to react with 
catalase molecules. Even when prednisolone-21-hemisuccinate 
was at a concentration of 1 mM, catalase was inactivated 
rapidly (Figs. 1 and 2). c~-Crystallin must therefore protect 
against steroid induced inactivation of catalase by direct inter- 
action with native or denatured catalase molecules. 
The stoichiometry of one molecule of ~-crystallin protect- 
ing two molecules of catalase against steroid-induced inactiva- 
tion is consistent with Carver's model of c~-crystallin [23]. This 
model suggests that c~-crystallin could have a quaternary 
structure similar to that of chaperonin 60 (GroEL). The sug- 
gested structure consists of two rings of a-crystallin subunits 
stacked on top of one another with a central cavity. Binding 
of a catalase molecule could occur within the cavity of each 
ring with the hydrophobic N-terminal domain of a-crystallin 
at the centre stabilising such a complex, although steric con- 
siderations could argue against an entire catalase molecule 
fitting in the centre of each ring. 
HPLC analysis trongly suggested that c~-crystallin did not 
protect catalase activity by formation of a stable complex with 
active catalase molecules. No significant formation of a higher 
molecular weight complex was observed throughout the incu- 
bation of catalase, prednisolone-21-hemisuccinate a d ~-crys- 
tallin. The significant increase of the c~-crystallin peak relative 
to that of the catalase peak is of interest. However, the pro- 
tection could be by a dynamic mechanism. 
Whether this protective ffect could happin in vivo is open 
to debate, but clearly such an effect would be highly desirable. 
With in vitro non-enzymic glycosylation of lens proteins and in 
human diabetic ataracts, lens proteins become modified, un- 
fold and aggregate [31,32]. Enzyme activities are reduced [2,3]. 
This could lead eventually to cataract. The fact that these 
changes occur with age and not immediately suggests that a 
molecule with properties exhibited in vitro by a-crystallin must 
exist. Beswick and Harding [31] have postulated that unfolding 
of lens proteins by sugars could lead to structures that resem- 
ble the molten globule state. Such a scheme could present 
many substrates for the chaperone properties of a-crystallin. 
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